New Push to Market Diabetic Drug Exubera - 8 News NOW

Paula Francis, Anchor

New Push to Market Diabetic Drug Exubera

Posted: Updated:

UPDATE: According to an Exubera spokesperson, both the Medicare Part B and Medicare Advantage-Part D (MA-PD) plans cover spirometry (breathing tests) for Exubera screening and monitoring, as long as they are coded properly.

-----------------------------------------------

You may have noticed an aggressive new ad campaign for a diabetes drug called Exubera. It's inhalant insulin. It's actually been available for a year, so why the big push now? Eye on Health asked Las Vegas endocrinologist, Fred Toffel.

At first, there was a lot of excitement about Exubera because the inhalant insulin seems like a great alternative to needles. Endocrinologist Fred Toffel says Exubera is effective, but a number of drawbacks have kept it from reaching high-volume sales.

He says that may be because it's complicated to use or because of its possible side effects on the lungs.

"Exubera requires some specialized training on how to teach a patient to use it properly," shared Toffel. "Additionally, since the medication is inhaled, one has to do pulmonary function tests ahead of time. And there are a lot of patients who do not qualify for the use of the medication."

In fact, there are a lot of diabetics who are unable to use Exubera, including those who are smokers or have a chronic lung condition. It's also not available for children.

For patients who can't afford the required lung tests, it can be a financial burden.

"Medicare, for instance, which is a big audience for people with diabetes, as we know 20% of people over 65 have diabetes, so that's a major audience, will not pay for the breathing tests for this drug, at least here in Nevada," said Toffel.

Dr. Toffel says there are two more inhalant insulins coming out soon that may be more user friendly.

  • Paula's Health NotesLas Vegas Health NewsMore>>

  • Prostate frozen lumpectomy offers patients an alternative

    Prostate frozen lumpectomy offers patients an alternative

    Tuesday, July 29 2014 3:39 PM EDT2014-07-29 19:39:02 GMT
    More than 230,000 men will be diagnosed with prostate cancer this year according to the American cancer society. In most cases, surgical removal of the gland is considered the gold standard of treatment, but results of a new study suggest a new treatment might benefit some patients.More>>
    More than 230,000 men will be diagnosed with prostate cancer this year according to the American cancer society. In most cases, surgical removal of the gland is considered the gold standard of treatment, but results of a new study suggest a new treatment might benefit some patients.More>>
  • New therapies for epilepsy

    New therapies for epilepsy

    Friday, July 25 2014 3:00 PM EDT2014-07-25 19:00:14 GMT
    pilepsy is a chronic neurological condition that affects more than 2.5 million Americans. Uncontrollable seizures plague these patients’ lives. Until now, the only treatments were drugs and major surgery, but new therapies are on the horizon.More>>
    pilepsy is a chronic neurological condition that affects more than 2.5 million Americans. Uncontrollable seizures plague these patients’ lives. Until now, the only treatments were drugs and major surgery, but new therapies are on the horizon.More>>
  • Study touts health care workers with less than bachelor's degree

    Study touts health care workers with less than bachelor's degree

    Thursday, July 24 2014 12:08 AM EDT2014-07-24 04:08:05 GMT
    Among Las Vegas workers with less than a bachelor’s degree only 3.5 percent hold jobs in the most common health care occupations, the lowest percentage among the nation’s 100 largest metropolitan areas, the Brookings Institution reported Wednesday night.More>>
    Among Las Vegas workers with less than a bachelor’s degree only 3.5 percent hold jobs in the most common health care occupations, the lowest percentage among the nation’s 100 largest metropolitan areas, the Brookings Institution reported Wednesday night.More>>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.